VEA
RPTX

Virtus ETF Advisers’s Repare Therapeutics RPTX Stock Holding History

Virtus ETF Advisers’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,808
Closed -$67K – 475
2023
Q1 		$67K Sell
6,808
-2,618
-28% -$30K 0.04% 406
2022
Q4 		$139K Buy
9,426
+1,789
+23% +$26.8K 0.07% 369
2022
Q3 		$93K Buy
7,637
+51
+0.7% +$656 0.04% 423
2022
Q2 		$106K Sell
7,586
-305
-4% -$3.59K 0.04% 417
2022
Q1 		$112K Sell
7,891
-464
-6% -$6.88K 0.05% 285
2021
Q4 		$176K Buy
8,355
+1,873
+29% +$44.1K 0.07% 261
2021
Q3 		$170K Sell
6,482
-346
-5% -$11.2K 0.07% 311
2021
Q2 		$213K Sell
6,828
-784
-10% -$25.7K 0.09% 301
2021
Q1 		$234K Buy
7,612
+143
+2% +$4.86K 0.1% 304
2020
Q4 		$256K Buy
+7,469
New +$223K 0.11% 304

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Virtus ETF Advisers's RPTX Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Repare Therapeutics (RPTX) in Q2 2023, closing a stake of 6,808 shares — an estimated $67K sold.

Virtus ETF Advisers first reported a position in RPTX in Q4 2020 and held it in 10 quarters. The position peaked at $256K in Q4 2020. 78 funds tracked by Wall St. Rank hold RPTX as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Repare Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,808 Repare Therapeutics shares in Q2 2023, an estimated $67K.
  • Virtus ETF Advisers first reported a position in Repare Therapeutics in Q4 2020 and held it in 10 quarters.
  • Virtus ETF Advisers's Repare Therapeutics position peaked at $256K in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.